Patents by Inventor Yuji Ochi
Yuji Ochi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9905338Abstract: An insulated electric cable 10 has a core member 1 formed by stranding a plurality of core wires 4, each of the core wires 4 including a conductor 5 and an insulating layer 6 covering the conductor 5, an inner sheath 7 covering the core member 1, an outer sheath 8 covering the inner sheath 7, and a paper tape 2 disposed between the core member 1 and the inner sheath 7 in a state that it is wrapped around the core member 1, in which the outer sheath 8 is formed by a flame-retardant polyurethane resin, and a cross-sectional area of each of conductors 5 is within 0.18-3.0 mm2.Type: GrantFiled: April 29, 2014Date of Patent: February 27, 2018Assignee: SUMITOMO ELECTRIC INDUSTRIES, LTD.Inventors: Satoshi Hashimoto, Yuji Ochi, Masayuki Ishikawa, Takami Sagisaka, Takaya Kohori
-
Publication number: 20180025808Abstract: An insulated electric cable 10 has a core member 1 formed by stranding a plurality of core wires 4, each of the core wires 4 including a conductor 5 and an insulating layer 6 covering the conductor 5, an inner sheath 7 covering the core member 1, an outer sheath 8 covering the inner sheath 7, and a paper tape 2 disposed between the core member 1 and the inner sheath 7 in a state that it is wrapped around the core member 1, in which the outer sheath 8 is formed by a flame-retardant polyurethane resin, and a cross-sectional area of each of conductors 5 is within 0.18-3.0 mm2.Type: ApplicationFiled: September 25, 2017Publication date: January 25, 2018Inventors: Satoshi HASHIMOTO, Yuji OCHI, Masayuki ISHIKAWA, Takami SAGISAKA, Takaya KOHORI
-
Patent number: 9805843Abstract: An insulated electric cable 10 has a core member 1 formed by stranding a plurality of core wires 4, each of the core wires 4 including a conductor 5 and an insulating layer 6 covering the conductor 5, an inner sheath 7 covering the core member 1, an outer sheath 8 covering the inner sheath 7, and a paper tape 2 disposed between the core member 1 and the inner sheath 7 in a state that it is wrapped around the core member 1, in which the outer sheath 8 is formed by a flame-retardant polyurethane resin, and a cross-sectional area of each of conductors 5 is within 0.18-3.0 mm2.Type: GrantFiled: April 29, 2014Date of Patent: October 31, 2017Assignee: SUMITOMO ELECTRIC INDUSTRIES, LTD.Inventors: Satoshi Hashimoto, Yuji Ochi, Masayuki Ishikawa, Takami Sagisaka, Takaya Kohori
-
Publication number: 20170004906Abstract: Provided is an insulated electric wire that mainly contains a polyolefin resin, has excellent flexibility, heat life, and waterproofness, and is used in wiring of vehicles such as automobiles, and an insulating resin composition used in forming an insulating layer of this insulated electric wire. The insulating resin composition contains a first copolymer, which is a copolymer of ethylene and an unsaturated hydrocarbon having 4 or more carbon atoms and which has a density less than 0.88 g/cm3, a second copolymer which is a copolymer of ethylene and an acrylic acid ester or a methacrylic acid ester, a flame retardant, and a crosslinking aid. Also provided is a crosslinked body having a 2% secant modulus of 35 MPa or less at room temperature and an elastic modulus of 2 MPa or more at 150° C.Type: ApplicationFiled: April 9, 2015Publication date: January 5, 2017Applicant: SUMITOMO ELECTRIC INDUSTRIES, LTD.Inventors: Shigeyuki TANAKA, Taro FUJITA, Shinya NISHIKAWA, Atsuko SHINOMIYA, Yuji OCHI
-
Publication number: 20160304461Abstract: The present invention provides a quinolone compound represented by General Formula (1) or a salt thereof, wherein R1 represents a hydrogen atom, etc.; R2 represents a hydrogen atom, etc.; R3 represents a phenyl group optionally being substituted with one or more substituents, etc.; R4 represents a halogen atom; R5 represents a hydrogen atom or halogen atom; R6 represents a hydrogen atom; and R7 represents a hydroxyl group, etc. The quinolone compound have a functional improvement effect, which suppresses progression of neurological dysfunction by inhibiting the chronic progression of Parkinson's disease or protecting dopamine neurons from the disease etiology, thereby prolonging the period before first administration begins.Type: ApplicationFiled: June 27, 2016Publication date: October 20, 2016Applicant: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Kenji OTSUBO, Yuji OCHI, Masami NAKAI, Atsushi MORI
-
Patent number: 9412497Abstract: An object of the invention is to provide a cable capable of matching exposed dimensions of conductors with a predetermined dimension to perform good processing at the time of distal end processing. In a cable (10) in which a pair of insulated wires (1) each of which is formed by covering a conductor (4) with an insulator (5) is mutually stranded and a periphery of these stranded insulated wires (1) is covered with a sheath (6) made of an inner sheath (2) and an outer sheath (3), the conductor (4) is formed by assembling a plurality of stranded wires (4a) each of which is formed by wholly stranding a plurality of wires (4b), and by further wholly stranding the stranded wires (4a).Type: GrantFiled: January 18, 2013Date of Patent: August 9, 2016Assignee: SUMITOMO ELECTRIC INDUSTRIES, LTD.Inventors: Satoshi Hashimoto, Yuji Ochi, Takaya Kohori, Takami Sagisaka, Yuhei Mayama
-
Patent number: 9403773Abstract: The present invention provides a quinolone compound represented by General Formula (1) or a salt thereof, wherein R1 represents a hydrogen atom, etc.; R2 represents a hydrogen atom, etc.; R3 represents a phenyl group optionally being substituted with one or more substituents, etc.; R4 represents a halogen atom; R5 represents a hydrogen atom or halogen atom; R6 represents a hydrogen atom; and R7 represents a hydroxyl group, etc. The quinolone compound have a functional improvement effect, which suppresses progression of neurological dysfunction by inhibiting the chronic progression of Parkinson's disease or protecting dopamine neurons from the disease etiology, thereby prolonging the period before first administration begins.Type: GrantFiled: April 15, 2015Date of Patent: August 2, 2016Assignee: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Kenji Otsubo, Yuji Ochi, Masami Nakai, Atsushi Mori
-
Publication number: 20150232653Abstract: The invention offers a heat-resistant flame-retardant rubber composition having low adhesiveness even in an uncrosslinked state, an insulated wire having an insulating covering composed of the heat-resistant flame-retardant rubber composition, and a rubber tube composed of the foregoing heat-resistant flame-retardant rubber composition. The heat-resistant flame-retardant rubber composition is formed by mixing 10 to 100 mass parts of an inorganic filler with 100 mass parts of a mixture produced by mixing (A) a vinylidene fluoride-hexafluoropropylene-based copolymer rubber and/or a vinylidene fluoride-hexafluoropropylene-tetrafluoroethylene-based copolymer rubber and (B) polyvinylidene fluoride at a mass ratio of 90:10 to 60:40. The insulated wire has an insulating covering composed of the rubber composition and irradiated with ionizing radiation. The rubber tube is composed of the foregoing heat-resistant flame-retardant rubber composition and irradiated with ionizing radiation.Type: ApplicationFiled: September 19, 2013Publication date: August 20, 2015Applicant: SUMITOMO ELECTRIC INDUSTRIES, LTD.Inventors: Taro Fujita, Hiroshi Hayami, Shinya Nishikawa, Yuji Ochi, Masahiro Tozawa
-
Publication number: 20150218101Abstract: The present invention provides a quinolone compound represented by General Formula (1) or a salt thereof, wherein R1 represents a hydrogen atom, etc.; R2 represents a hydrogen atom, etc.; R3 represents a phenyl group optionally being substituted with one or more substituents, etc.; R4 represents a halogen atom; R5 represents a hydrogen atom or halogen atom; R6 represents a hydrogen atom; and R7 represents a hydroxyl group, etc. The quinolone compound have a functional improvement effect, which suppresses progression of neurological dysfunction by inhibiting the chronic progression of Parkinson's disease or protecting dopamine neurons from the disease etiology, thereby prolonging the period before first administration begins.Type: ApplicationFiled: April 15, 2015Publication date: August 6, 2015Applicant: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Kenji OTSUBO, Yuji OCHI, Masami NAKAI, Atsushi MORI
-
Patent number: 9045464Abstract: The present invention provides a quinolone compound represented by General Formula (1) or a salt thereof, wherein R1 represents a hydrogen atom, etc.; R2 represents a hydrogen atom, etc.; R3 represents a phenyl group optionally being substituted with one or more substituents, etc.; R4 represents a halogen atom; R5 represents a hydrogen atom or halogen atom; R6 represents a hydrogen atom; and R7 represents a hydroxyl group, etc. The quinolone compound have a functional improvement effect, which suppresses progression of neurological dysfunction by inhibiting the chronic progression of Parkinson's disease or protecting dopamine neurons from the disease etiology, thereby prolonging the period before first administration begins.Type: GrantFiled: January 3, 2014Date of Patent: June 2, 2015Assignee: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Kenji Otsubo, Yuji Ochi, Masami Nakai, Atsushi Mori
-
Publication number: 20150144375Abstract: An object of the invention is to provide a cable capable of matching exposed dimensions of conductors with a predetermined dimension to perform good processing at the time of distal end processing. In a cable (10) in which a pair of insulated wires (1) each of which is formed by covering a conductor (4) with an insulator (5) is mutually stranded and a periphery of these stranded insulated wires (1) is covered with a sheath (6) made of an inner sheath (2) and an outer sheath (3), the conductor (4) is formed by assembling a plurality of stranded wires (4a) each of which is formed by wholly stranding a plurality of wires (4b), and by further wholly stranding the stranded wires (4a).Type: ApplicationFiled: January 18, 2013Publication date: May 28, 2015Inventors: Satoshi Hashimoto, Yuji Ochi, Takaya Kohori, Takami Sagisaka, Yuhei Mayama
-
Patent number: 9018229Abstract: The present invention provides a quinolone compound that inhibits the chronic progression of Parkinson's disease or protects dopamine neurons from disease etiology, thereby suppressing the progression of neurological dysfunction, so as to prolong the period of time until L-dopa is administered while also improving neuronal function; the quinolone compound of the invention is represented by Formula (1): wherein: R1 represents hydrogen or the like; R2 represents hydrogen or the like; R3 represents substituted or unsubstituted phenyl or the like; R4 represents halogen or the like; R5 represents hydrogen or the like; R6 represents hydrogen or the like; and R7 represents hydrogen or the like.Type: GrantFiled: October 18, 2013Date of Patent: April 28, 2015Assignee: Otsuka Pharmaceutical Co., Ltd.Inventors: Kenji Otsubo, Takahito Yamauchi, Yuji Ochi
-
Publication number: 20140326480Abstract: An insulated electric cable 10 has a core member 1 formed by stranding a plurality of core wires 4, each of the core wires 4 including a conductor 5 and an insulating layer 6 covering the conductor 5, an inner sheath 7 covering the core member 1, an outer sheath 8 covering the inner sheath 7, and a paper tape 2 disposed between the core member 1 and the inner sheath 7 in a state that it is wrapped around the core member 1, in which the outer sheath 8 is formed by a flame-retardant polyurethane resin, and a cross-sectional area of each of conductors 5 is within 0.18-3.0 mm2.Type: ApplicationFiled: April 29, 2014Publication date: November 6, 2014Applicant: SUMITOMO ELECTRIC INDUSTRIES, LTD.Inventors: Satoshi HASHIMOTO, Yuji OCHI, Masayuki ISHIKAWA, Takami SAGISAKA, Takaya KOHORI
-
Publication number: 20140121207Abstract: The present invention provides a quinolone compound represented by General Formula (1) or a salt thereof, wherein R1 represents a hydrogen atom, etc.; R2 represents a hydrogen atom, etc.; R3 represents a phenyl group optionally being substituted with one or more substituents, etc.; R4 represents a halogen atom; R5 represents a hydrogen atom or halogen atom; R6 represents a hydrogen atom; and R7 represents a hydroxyl group, etc. The quinolone compound have a functional improvement effect, which suppresses progression of neurological dysfunction by inhibiting the chronic progression of Parkinson's disease or protecting dopamine neurons from the disease etiology, thereby prolonging the period before first administration begins.Type: ApplicationFiled: January 3, 2014Publication date: May 1, 2014Applicant: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Kenji OTSUBO, Yuji OCHI, Masami NAKAI, Atsushi MORI
-
Publication number: 20140045793Abstract: The present invention provides a quinolone compound that inhibits the chronic progression of Parkinson's disease or protects dopamine neurons from disease etiology, thereby suppressing the progression of neurological dysfunction, so as to prolong the period of time until L-dopa is administered while also improving neuronal function; the quinolone compound of the invention is represented by Formula (1): wherein: R1 represents hydrogen or the like; R2 represents hydrogen or the like; R3 represents substituted or unsubstituted phenyl or the like; R4 represents halogen or the like; R5 represents hydrogen or the like; R6 represents hydrogen or the like; and R7 represents hydrogen or the like.Type: ApplicationFiled: October 18, 2013Publication date: February 13, 2014Applicant: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Kenji OTSUBO, Takahito YAMAUCHI, Yuji OCHI
-
Patent number: 8642619Abstract: The present invention provides a quinolone compound represented by General Formula (1) or a salt thereof, wherein R1 represents a hydrogen atom, etc.; R2 represents a hydrogen atom, etc.; R3 represents a phenyl group optionally being substituted with one or more substituents, etc.; R4 represents a halogen atom; R5 represents a hydrogen atom or halogen atom; R6 represents a hydrogen atom; and R7 represents a hydroxyl group, etc. The quinolone compound have a functional improvement effect, which suppresses progression of neurological dysfunction by inhibiting the chronic progression of Parkinson's disease or protecting dopamine neurons from the disease etiology, thereby prolonging the period before first administration begins.Type: GrantFiled: August 21, 2012Date of Patent: February 4, 2014Assignee: Otsuka Pharmaceutical Co., Ltd.Inventors: Kenji Otsubo, Yuji Ochi, Masami Nakai, Atsushi Mori
-
Patent number: 8592593Abstract: The present invention provides a quinolone compound that inhibits the chronic progression of Parkinson's disease or protects dopamine neurons from disease etiology, thereby suppressing the progression of neurological dysfunction, so as to prolong the period of time until L-dopa is administered while also improving neuronal function; the quinolone compound of the invention is represented by Formula (1): wherein: R1 represents hydrogen or the like; R2 represents hydrogen or the like; R3 represents substituted or unsubstituted phenyl or the like; R4 represents halogen or the like; R5 represents hydrogen or the like; R6 represents hydrogen or the like; and R7 represents hydrogen or the like.Type: GrantFiled: September 14, 2012Date of Patent: November 26, 2013Assignee: Otsuka Pharmaceutical Co., Ltd.Inventors: Kenji Otsubo, Takahito Yamauchi, Yuji Ochi
-
Publication number: 20130005675Abstract: The present invention provides a quinolone compound that inhibits the chronic progression of Parkinson's disease or protects dopamine neurons from disease etiology, thereby suppressing the progression of neurological dysfunction, so as to prolong the period of time until L-dopa is administered while also improving neuronal function; the quinolone compound of the invention is represented by Formula (1): wherein: R1 represents hydrogen or the like; R2 represents hydrogen or the like; R3 represents substituted or unsubstituted phenyl or the like; R4 represents halogen or the like; R5 represents hydrogen or the like; R6 represents hydrogen or the like; and R7 represents hydrogen or the like.Type: ApplicationFiled: September 14, 2012Publication date: January 3, 2013Applicant: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Kenji OTSUBO, Takahito YAMAUCHI, Yuji OCHI
-
Publication number: 20120316168Abstract: The present invention provides a quinolone compound represented by General Formula (1) or a salt thereof, wherein R1 represents a hydrogen atom, etc.; R2 represents a hydrogen atom, etc.; R3 represents a phenyl group optionally being substituted with one or more substituents, etc.; R4 represents a halogen atom; R5 represents a hydrogen atom or halogen atom; R6 represents a hydrogen atom; and R7 represents a hydroxyl group, etc. The quinolone compound have a functional improvement effect, which suppresses progression of neurological dysfunction by inhibiting the chronic progression of Parkinson's disease or protecting dopamine neurons from the disease etiology, thereby prolonging the period before first administration begins.Type: ApplicationFiled: August 21, 2012Publication date: December 13, 2012Applicant: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Kenji OTSUBO, Yuji OCHI, Masami NAKAI, Atsushi MORI
-
Patent number: RE45108Abstract: The present invention provides a quinolone compound that inhibits the chronic progression of Parkinson's disease or protects dopamine neurons from disease etiology, thereby suppressing the progression of neurological dysfunction, so as to prolong the period of time until L-dopa is administered while also improving neuronal function; the quinolone compound of the invention is represented by Formula (1): wherein: R1 represents hydrogen or the like; R2 represents hydrogen or the like; R3 represents substituted or unsubstituted phenyl or the like; R4 represents halogen or the like; R5 represents hydrogen or the like; R6 represents hydrogen or the like; and R7 represents hydrogen or the like.Type: GrantFiled: September 27, 2013Date of Patent: September 2, 2014Assignee: Otsuka Pharmaceutical Co., Ltd.Inventors: Kenji Otsubo, Takahito Yamauchi, Yuji Ochi